Does treatment with anti-IL-17 affect HbA1c levels?

Data on 71 patients with psoriasis. We aimed to assess the potential correlation between PASI and HbA1c and investigate the antidiabetic role of anti-IL-17A and anti-IL-12/-23. Only biologic-naïve patients were included. Description of column values: PASI1: PASI at baseline PASI2: First PASI measurement available after at least 120 days of treatment. HbA1c1: HbA1c at baseline (measured maximum 90 days before beginning treatment) HbA1c2: First HbA1c measurement available after at least 120 days of treatment. We used Spearman’s rank correlation coefficient to assess the relationship between baseline PASI scores and HbA1c levels. Additionally, to compare changes in HbA1c, we used the Wilcoxon signed rank test as data were not normally distributed. We found no correlation between PASI scores and HbA1c levels and no evidence for an overall change in HbA1c related to biologic treatment with secukinumab or ustekinumab.本数据集涵盖71名银屑病患者的相关数据。本研究旨在评估银屑病面积和严重程度指数（PASI，Psoriasis Area and Severity Index）与糖化血红蛋白（HbA1c，Glycated Hemoglobin A1c）之间的潜在相关性，并探讨抗IL-17A与抗IL-12/-23制剂的抗糖尿病作用。本研究仅纳入生物制剂初治患者。各列数据说明如下：PASI1为基线期银屑病面积和严重程度指数评分；PASI2为患者接受至少120天治疗后首次测得的PASI评分。HbA1c1为基线期糖化血红蛋白水平（检测时间距治疗起始时间最长不超过90天）；HbA1c2为患者接受至少120天治疗后首次测得的糖化血红蛋白水平。本研究采用斯皮尔曼等级相关系数评估基线PASI评分与HbA1c水平之间的关联。鉴于数据不符合正态分布，我们采用威尔科克森符号秩检验以比较糖化血红蛋白的变化情况。研究结果显示，PASI评分与HbA1c水平之间未发现显著相关性，且未发现司库奇尤单抗（secukinumab）或乌司奴单抗（ustekinumab）的生物制剂治疗会引起糖化血红蛋白总体水平变化的相关证据。